24-Week study to evaluate the efficacy/safety of transdermal testosterone in naturally menopausal women with hypoactive sexual desire disorder receiving systemic transdermal estrogen therapy

Trial Profile

24-Week study to evaluate the efficacy/safety of transdermal testosterone in naturally menopausal women with hypoactive sexual desire disorder receiving systemic transdermal estrogen therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2013

At a glance

  • Drugs Testosterone (Primary)
  • Indications Decreased libido; Female sexual dysfunction
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ADORE
  • Sponsors Procter & Gamble
  • Most Recent Events

    • 01 Apr 2010 Results published in Climacteric.
    • 30 Mar 2010 Warner Chilcott Company added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
    • 21 Jul 2009 Actual number of patients (272) added as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top